Head-to-head · Cost-Efficiency Index
Obu Health vs Tablet Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Obu Health
Cost-first shoppers who want comparing headline monthly prices without needing pharmacy or prescriber names published up front.
Visit Obu HealthTablet Health
Cost-first shoppers who want an oral-tablet GLP-1 option at the lowest published tier ($179/mo), if you can tolerate no state-coverage list.
Visit Tablet HealthThe verdict
Obu Health and Tablet Health tie on the Cost-Efficiency Index at 57/100, so neither wins outright on the numbers. For most shoppers we'd start with Obu Health (ranked #310, a hair above #315) — Cost-first shoppers who want comparing headline monthly prices without needing pharmacy or prescriber names published up front. But Tablet Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Obu Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Obu Health | Tablet Health |
|---|---|---|
| Cost-Efficiency Index | 57/100 | 57/100 |
| Semaglutide / mo | $190/mo (starting dose, compounded) | $199/mo (compounded) |
| Tirzepatide / mo | $239/mo (starting dose, compounded) | $299/mo (compounded) |
| Semaglutide / yr (modeled) | $2,280 | $2,388 |
| Tirzepatide / yr (modeled) | $2,868 | $3,588 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #310 | #315 |
Obu Health
57/100Where the value is
- Real starting dollar figures published directly on the homepage without requiring intake — $190/mo semaglutide, $239/mo tirzepatide
- LegitScript certification badge displayed
- Sells adjacent longevity products (NAD+ at $219, Sermorelin starting $149/mo) on the same platform
The tradeoffs
- 'Starting' pricing means the $190/$239 figures are floors — no page found discloses whether cost rises with dose or what a maintenance dose costs
- No medical director, individually named prescriber, or compounding pharmacy is disclosed anywhere on the site
Tablet Health
57/100Where the value is
- LegitScript Certified — seal displayed on the site
- Offers both oral-tablet and injectable forms of semaglutide AND tirzepatide, four distinct SKUs
- Published per-product pricing rather than a single vague 'starting at' figure: $179-$299/mo across the four variants
The tradeoffs
- States served are not published anywhere on the accessible site — eligibility is only revealed by completing the intake quiz
- The homepage's 'Flat monthly pricing starting at $149' banner cannot be tied to any of the four listed $179-$299 tiers
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.